

Eva M Lonn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2469568/publications.pdf>

Version: 2024-02-01

62
papers

9,245
citations

159585

30
h-index

123424

61
g-index

62
all docs

62
docs citations

62
times ranked

11399
citing authors

#	ARTICLE	IF	CITATIONS
1	Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. <i>New England Journal of Medicine</i> , 2006, 354, 1567-1577.	27.0	1,536
2	Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1338.	7.4	1,083
3	Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. <i>Annals of Internal Medicine</i> , 1999, 131, 363.	3.9	781
4	Effects of Ramipril and Vitamin E on Atherosclerosis. <i>Circulation</i> , 2001, 103, 919-925.	1.6	698
5	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	27.0	641
6	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	27.0	526
7	Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. <i>Circulation</i> , 2001, 104, 1615-1621.	1.6	502
8	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 205-218.	13.7	426
9	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. <i>Diabetes Care</i> , 2002, 25, 1919-1927.	8.6	349
10	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	27.0	299
11	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
12	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
13	Effects of Ramipril on Coronary Events in High-Risk Persons. <i>Circulation</i> , 2001, 104, 522-526.	1.6	181
14	The Polypill in the Prevention of Cardiovascular Diseases. <i>Circulation</i> , 2010, 122, 2078-2088.	1.6	152
15	Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular Events. <i>PLoS ONE</i> , 2015, 10, e0132321.	2.5	141
16	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	1.7	133
17	Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. <i>Clinical Research in Cardiology</i> , 2014, 103, 149-159.	3.3	117
18	Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2014, 64, 731-737.	2.7	111

#	ARTICLE	IF	CITATIONS
19	The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1189-1194.	1.7	111
20	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	2.2	101
21	Primary Prevention With Statin Therapy in the Elderly. <i>Circulation</i> , 2017, 135, 1979-1981.	1.6	97
22	Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2200-2206.	2.8	93
23	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. <i>Lancet, The</i> , 2021, 398, 1133-1146.	13.7	87
24	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	2.8	69
25	Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2254-2259.	2.4	68
26	Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2028-2035.	2.8	54
27	Effect of long-term therapy with ramipril in high-risk women. <i>Journal of the American College of Cardiology</i> , 2002, 40, 693-702.	2.8	52
28	Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. <i>Diabetes Care</i> , 2013, 36, 2466-2474.	8.6	40
29	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2002, 4, 363-372.	4.8	33
30	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 420-428.	2.8	33
31	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	1.7	25
32	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	1.7	24
33	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq1 1 0.784314 zgBT /Over		
34	Polypill: the evidence and the promise. <i>Current Opinion in Lipidology</i> , 2009, 20, 453-459.	2.7	18
35	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	2.2	18
36	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 113-120.	0.3	18

#	ARTICLE	IF	CITATIONS
37	Brief Vigorous Stair Climbing Effectively Improves Cardiorespiratory Fitness in Patients With Coronary Artery Disease: A Randomized Trial. <i>Frontiers in Sports and Active Living</i> , 2021, 3, 630912.	1.8	17
38	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	3.8	17
39	The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-Lowering Trials. <i>JAMA Cardiology</i> , 2016, 1, 857.	6.1	15
40	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
41	Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1305-1311.	1.7	14
42	Clustering of cardiovascular risk factors and carotid intima-media thickness: The USE-IMT study. <i>PLoS ONE</i> , 2017, 12, e0173393.	2.5	13
43	Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 600-606.	1.5	12
44	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	5.9	11
45	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	6.8	11
46	Drug Therapies in the Secondary Prevention of Cardiovascular Diseases: Successes, Shortcomings and Future Directions. <i>Current Vascular Pharmacology</i> , 2006, 4, 253-268.	1.7	10
47	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021, 52, 2494-2501.	2.0	10
48	Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 681-697.	1.8	6
49	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
50	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017, 33, 940-942.	1.7	5
51	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1350-1361.	1.7	4
52	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
53	Cardiovascular responses to high-intensity stair climbing in individuals with coronary artery disease. <i>Physiological Reports</i> , 2022, 10, e15308.	1.7	4
54	Lipoprotein-associated phospholipase A2: A new therapeutic target. <i>Canadian Journal of Cardiology</i> , 2010, 26, 27A-31A.	1.7	3

#	ARTICLE	IF	CITATIONS
55	The role of icosapent ethyl in cardiovascular risk reduction. <i>Current Opinion in Cardiology</i> , 2021, 36, 661-671.	1.8	3
56	Young Women With Acute Myocardial Infarction and the Posthospital Syndrome. <i>Circulation</i> , 2015, 132, 149-151.	1.6	2
57	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. <i>CJC Open</i> , 2019, 1, 190-197.	1.5	2
58	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	1
59	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019, 35, 644-652.	1.7	1
60	What do physicians need to know in order to "prescribe" mobile applications to patients with cardiovascular disease?. <i>Personalized Medicine</i> , 2019, 16, 263-268.	1.5	1
61	The clinical relevance of pharmacological blood pressure lowering mechanisms. <i>Canadian Journal of Cardiology</i> , 2004, 20 Suppl B, 83B-88B.	1.7	1
62	Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study. <i>Open Cardiovascular Medicine Journal</i> , 2014, 8, 94-101.	0.3	0